It can specifically bind tumors via a molecular interaction with Annexin A2 and matrix metalloproteinase 2.[34] Conjugated with ICG, BLZ-100 (tozuleristide or Tumor Paint) was demonstrated to be a tumor-bound agent that can be used in high- and low-grade glioma, for example, GBM, astrocytoma, ependymoma, and meningioma in vitro.[14,15] In a phase I human clinical study, BLZ-100 demonstrated its greater fluorescence intensity in high-grade glioma as compared to low-grade glioma. The gene discussed is ANXA2; the disease is glioma.